Reason for request
Reassessment
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of LYNPARZA (olaparib), monotherapy, remains substantial in the MA indication.
|
Clinical Added Value
| minor |
In view of:
- the evidence of the superiority of olaparib monotherapy versus placebo, in a randomised double-blind study, in terms of investigator-assessed progression-free survival: HR=0.30 [95%CI: 0.23-0.41], with a median progression-free survival not reached in the olaparib group and of 13.8 months in the placebo group,
- the lack of evidence of superiority on overall survival, despite the new data submitted,
- the lack of formal conclusion that can be drawn from the quality-of-life findings,
- the safety profile of olaparib, with in particular the onset of myelodysplastic syndromes/acute myeloid leukaemia,
the Committee deems that LYNPARZA (olaparib) monotherapy provides minor clinical added value (CAV IV) in the therapeutic strategy.
|
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
cQy4dVWTrnGY88p6